EP1986619A4 - Use of phosphatases to treat tumors overexpressing n-cor - Google Patents

Use of phosphatases to treat tumors overexpressing n-cor

Info

Publication number
EP1986619A4
EP1986619A4 EP07763614A EP07763614A EP1986619A4 EP 1986619 A4 EP1986619 A4 EP 1986619A4 EP 07763614 A EP07763614 A EP 07763614A EP 07763614 A EP07763614 A EP 07763614A EP 1986619 A4 EP1986619 A4 EP 1986619A4
Authority
EP
European Patent Office
Prior art keywords
phosphatases
cor
treat tumors
tumors overexpressing
overexpressing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07763614A
Other languages
German (de)
French (fr)
Other versions
EP1986619A2 (en
Inventor
Zhengping Zhuang
Edward H Oldfield
Deric M Park
Irina Lubensky
Jie Li
John S Kovach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of United States, a
Lixte Biotechnology Inc
Original Assignee
US Department of Health and Human Services
Lixte Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Lixte Biotechnology Inc filed Critical US Department of Health and Human Services
Publication of EP1986619A2 publication Critical patent/EP1986619A2/en
Publication of EP1986619A4 publication Critical patent/EP1986619A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
EP07763614A 2006-02-06 2007-02-06 Use of phosphatases to treat tumors overexpressing n-cor Withdrawn EP1986619A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77116306P 2006-02-06 2006-02-06
US79720106P 2006-05-02 2006-05-02
PCT/US2007/003095 WO2007092414A2 (en) 2006-02-06 2007-02-06 Use of phosphatases to treat tumors overexpressing n-cor

Publications (2)

Publication Number Publication Date
EP1986619A2 EP1986619A2 (en) 2008-11-05
EP1986619A4 true EP1986619A4 (en) 2010-04-28

Family

ID=38345726

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07763614A Withdrawn EP1986619A4 (en) 2006-02-06 2007-02-06 Use of phosphatases to treat tumors overexpressing n-cor

Country Status (3)

Country Link
EP (1) EP1986619A4 (en)
CA (1) CA2641308A1 (en)
WO (1) WO2007092414A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008347A (en) 2007-02-06 2009-10-19 Lixte Biotechnology Holdings I Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
EP2185173A4 (en) * 2007-08-03 2011-01-12 Lixte Biotechnology Inc Use of phosphatases to treat neuroblastomas and medullogastomas
AU2008307541B2 (en) 2007-10-01 2015-02-12 Lixte Biotechnology, Inc. HDAC inhibitors
CA2730428A1 (en) * 2008-08-01 2010-02-04 Lixte Biotechnology, Inc. Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
WO2010147612A1 (en) * 2009-06-18 2010-12-23 Lixte Biotechnology, Inc. Methods of modulating cell regulation by inhibiting p53
WO2011097712A1 (en) * 2010-02-11 2011-08-18 The Royal Institution For The Advancement Of Learning/Mcgill University Hybrid molecule having mixed retinoic acid receptor agonism and histone deacetylase inhibitory properties
AU2013282365A1 (en) 2012-06-29 2015-02-19 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of diabetes
MX2015014249A (en) 2013-04-09 2016-06-02 Lixte Biotechnology Inc Formulations of oxabicycloheptanes and oxabicycloheptenes.
WO2016014783A1 (en) 2014-07-24 2016-01-28 H. Lee Moffitt Cancer Center And Research Institute, Inc. Protein phosphatase 2a inhibitors for treating myelodysplastic syndromes
US9833450B2 (en) 2015-02-19 2017-12-05 Lixte Biotechnology, Inc. Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders
EP3736275A1 (en) 2015-05-15 2020-11-11 Lixte Biotechnology, Inc. Oxabicycloheptane prodrugs for use in treating cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
WO2002009680A2 (en) * 2000-08-02 2002-02-07 Michael Walter Pharmacologically active substance for treating cardiovascular disorders
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
WO2003092719A2 (en) * 2002-04-29 2003-11-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for modulating beta-catenin phosphorylation
US20040209934A1 (en) * 2001-03-23 2004-10-21 Mccluskey Adam Protein phosphate inhibitors
FR2872704A1 (en) * 2004-07-12 2006-01-13 Laurent Schwartz PLURITHERAPY AGAINST CANCER

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262116B1 (en) * 1998-01-23 2001-07-17 Sloan-Kettering Institute For Cancer Research Transcription therapy for cancers
WO2002009680A2 (en) * 2000-08-02 2002-02-07 Michael Walter Pharmacologically active substance for treating cardiovascular disorders
WO2002028387A1 (en) * 2000-10-03 2002-04-11 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US20040209934A1 (en) * 2001-03-23 2004-10-21 Mccluskey Adam Protein phosphate inhibitors
WO2003092719A2 (en) * 2002-04-29 2003-11-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for modulating beta-catenin phosphorylation
FR2872704A1 (en) * 2004-07-12 2006-01-13 Laurent Schwartz PLURITHERAPY AGAINST CANCER

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FRASOR JONNA ET AL: "Estrogen down-regulation of the corepressor N-CoR: Mechanism and implications for estrogen derepression of N-CoR-regulated genes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 37, September 2005 (2005-09-01), pages 13153 - 13157, XP002572866, ISSN: 0027-8424 *
HILL ET AL: "Heterocyclic substituted cantharidin and norcantharidin analogues-synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 12, 15 June 2007 (2007-06-15), pages 3392 - 3397, XP022097790, ISSN: 0960-894X *
KOK S-H ET AL: "Norcantharidin-induced apoptosis in oral cancer cells is associated with an increase of proapoptotic to antiapoptotic protein ratio", CANCER LETTERS, NEW YORK, NY, US, vol. 217, no. 1, 10 January 2005 (2005-01-10), pages 43 - 52, XP004681287, ISSN: 0304-3835 *
LEE MI-OCK ET AL: "Role of coactivators and corepressors in the induction of the RARbeta gene in human colon cancer cells.", BIOLOGICAL AND PHARMACEUTICAL BULLETIN, vol. 25, no. 10, October 2002 (2002-10-01), pages 1298 - 1302, XP002572865, ISSN: 0918-6158 *

Also Published As

Publication number Publication date
WO2007092414A8 (en) 2008-09-04
CA2641308A1 (en) 2007-08-16
WO2007092414A3 (en) 2008-05-15
WO2007092414A2 (en) 2007-08-16
EP1986619A2 (en) 2008-11-05

Similar Documents

Publication Publication Date Title
EP1986619A4 (en) Use of phosphatases to treat tumors overexpressing n-cor
IL248204A0 (en) Combination treatment of cd38-expressing tumors
HK1245098A1 (en) Methods of treating chronic pain
IL204541A0 (en) Use of mva to treat prostate cancer
HK1207578A1 (en) Treatment of synucleinopathies
EP2049139A4 (en) Treatment of ras-expressing tumors
IL194198A0 (en) Administration of ketamine to treat depression
EP2370582A4 (en) Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
EP2066589A4 (en) System of water treatment
EP2026843A4 (en) Therapeutic uses of inhibitors of rtp801l
IL197315A0 (en) Treatment of cancer
EP2068864A4 (en) Therapeutic uses of urolithins
EP2185173A4 (en) Use of phosphatases to treat neuroblastomas and medullogastomas
EP1991230A4 (en) Methods of treating cancer
ZA201008140B (en) Treatment of metastatic tumors
PL2274005T3 (en) Treatment of tumors by angiotensin converting enzyme 2 (ace2)
EP2300608A4 (en) Methods to treat solid tumors
PL2049127T3 (en) N-methanocarba derivatives to treat cardiac diseases
EP1987838A4 (en) Novel compound for treatment of tumor
EP1986682A4 (en) Methods and compositions related to targeting tumors and wounds
EP1986660A4 (en) Hexose compounds to treat cancer
EP2249765A4 (en) Dapsone to treat rosascea
EP2056839A4 (en) Combination approaches to cancer treatment
ZA200902765B (en) Treatment of pulp
EP2043663A4 (en) Topical treatment of warts

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080904

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KOVACH, JOHN, S.

Inventor name: LI, JIE

Inventor name: LUBENSKY, IRINA

Inventor name: PARK, DERIC, M.

Inventor name: OLDFIELD, EDWARD, H.

Inventor name: ZHUANG, ZHENGPING

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE GOVERNMENT OF THE UNITED STATES OF AMERICA A

Owner name: LIXTE BIOTECHNOLOGY, INC.

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20100318BHEP

Ipc: A61K 31/00 20060101AFI20080912BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20100330

17Q First examination report despatched

Effective date: 20110411

DAX Request for extension of the european patent (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/519 20060101ALI20140610BHEP

Ipc: A61P 35/00 20060101ALI20140610BHEP

Ipc: A61K 31/00 20060101AFI20140610BHEP

INTG Intention to grant announced

Effective date: 20140703

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20141114